文献速递外周动脉疾病

主双股动脉旁路术与主髂动脉分叉重建支架术治疗TASC II D主髂动脉闭塞性疾病的比较

Comparison of Aortobifemoral Bypass to Aortoiliac Stenting with Bifurcation Reconstruction for TASC II D Aortoiliac Occlusive Disease.
PubMed 文献 · Ann Vasc Surg · 2021-11-14

单中心回顾性研究比较2010至2018年TASC II D主髂动脉闭塞性疾病患者接受主双股动脉旁路术(ABF,24例)与主髂动脉分叉重建支架术(AISBR,75例)的结果。AISBR组术中失血量、手术时间和住院时间显著更少,手术部位感染更少(6/75 vs 9/24,P<0.01),但5年原发通畅率较低(50.8% vs 88.1%,P=0.04),5年生存率两组无显著差异(P=0.07)。

要点

  • AISBR组手术部位感染6/75(8.0%)显著低于ABF组9/24(37.5%)(P<0.01)。
  • AISBR组5年原发通畅率50.8%(95%CI 33.3-68.4%)低于ABF组88.1%(95%CI 72.7-100.0%)(P=0.04)。
  • AISBR组术中失血量、手术时间和住院时间显著少于ABF组。

核心结论

  • AISBR是治疗TASC II D主髂动脉闭塞性疾病的可行选择,与传统ABF相比发病率更低且耐久性可接受。

研究设计与样本

  • 单中心回顾性研究,纳入2010至2018年因可比TASC II D病变接受ABF或AISBR治疗的患者,ABF组仅纳入术前影像评估认为也适合AISBR的解剖学候选者,排除急性肢体缺血和旁路移植物感染患者。
  • 共纳入24例ABF和75例AISBR患者。

主要发现

  • 治疗指征为间歇性跛行55例(55.6%)、静息痛28例(28.3%)、组织缺损16例(16.2%)。
  • AISBR组女性比例更高;股动脉内膜切除术在AISBR组为37/75(49.3%),ABF组为14/24(58.3%)(P=0.44);AISBR组34/75(45.1%)经皮完成,无AISBR中转ABF。
  • AISBR组术中失血量、手术时间和住院时间显著少于ABF组;手术部位感染AISBR组6/75(8.0%)vs ABF组9/24(37.5%)(P<0.01);AISBR组1例和ABF组2例发生术后30天以上晚期手术部位感染;排除经皮AISBR后失血量、住院时间和手术部位感染的降低仍显著。
  • 5年原发通畅率AISBR组50.8%(95%CI 33.3-68.4%)vs ABF组88.1%(95%CI 72.7-100.0%)(P=0.04);5年生存率AISBR组76.5%(95%CI 63.6-89.5)vs ABF组100%(95%CI 100.0-100.0)(P=0.07)。
  • 5年原发辅助通畅率、二期通畅率、免于再干预率和主要不良肢体事件两组无显著差异。

临床怎么用

  • 作者认为AISBR是治疗TASC II D主髂动脉闭塞性疾病的可行选择,与传统ABF相比发病率更低且耐久性可接受。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-segment stenting of the infrarenal aorta and bilateral iliac arteries, with or without femoral endarterectomy for diffuse disease, has been adopted for treatment of severe aortoiliac occlusive disease (AIOD). The objective of this study was to compare outcomes of this reconstruction, termed aortoiliac stenting with bifurcation reconstruction (AISBR), to aortobifemoral bypass (ABF) in patients with comparable TASC II D lesions. METHODS: This is a single-center, retrospective review of patients treated with ABF or AISBR for comparable TASC II D lesions between 2010 and 2018. ABF patients were included only if they were deemed anatomic candidates also for AISBR after review of preoperative imaging. Patients treated for acute limb ischemia and bypass graft infection were excluded. Statistics included Fisher exact test, Kaplan-Meier analysis, and Cox proportional hazards regression. RESULTS: There were 24 ABF and 75 AISBR included in the study. The primary indication for treatment was claudication in 55 (55.6%) patients, rest pain in 28 (28.3%), and tissue loss in 16 (16.2%). Patients undergoing AISBR were more likely to be female. Femoral endarterectomies were performed in 37/75 (49.3%) AISBR and 14/24 (58.3%) ABF (P = 0.44). AISBR were performed percutaneously in 34/75 (45.1%). No AISBR required conversion to ABF. Intraoperative blood loss, procedure time and hospital length of stay (LOS) were significantly less for AISBR compared to ABF. Surgical site infections (SSI) were less common in patients undergoing AISBR (AISBR: 6/75 (8.0%) vs. ABF: 9/24 (37.5%), (P< 0.01). One AISBR and two 2 ABF developed late SSI >30 days postoperatively. The reductions in blood loss, LOS and SSI remained significant after excluding percutaneous AISBR from the analysis. Five-year primary patency was 50.8% (95% CI: 33.3, 68.4%) for AISBR and 88.1% (72.7, 100.0%) for ABF (P= 0.04). Five-year survival was 76.5% (95% CI: 63.6, 89.5) for AISBR and 100% (95% CI: 100.0, 100.0) for ABF (P = 0.07). Five-year primary assisted patency, secondary patency, freedom from reintervention and major adverse limb events did not differ significantly between groups. CONCLUSIONS: AISBR is a viable option for management of TASC II D AIOD, with lower morbidity and acceptable durability when compared to traditional ABF.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Smith AH, Beach JM, Dash S, et al. Comparison of Aortobifemoral Bypass to Aortoiliac Stenting with Bifurcation Reconstruction for TASC II D Aortoiliac Occlusive Disease. Ann Vasc Surg. 2021. PMID: 34788703. doi:10.1016/j.avsg.2021.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。